Document Detail


Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study.
MedLine Citation:
PMID:  21354230     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND & AIMS: In patients with cirrhosis and refractory ascites the role of beta-blockers in the development of paracentesis-induced circulatory dysfunction (PICD) is unknown. The aim of this study was to investigate the incidence of PICD before and after discontinuation of beta-blockers in patients with cirrhosis and refractory ascites. A self control cross-over study was performed.
METHODS: Patients with cirrhosis and refractory ascites treated with beta-blockers were selected. Heart rate, arterial pressure, and plasma renin concentrations (PRC) were collected before, immediately after and 1 week after large-volume paracentesis associated with intravenous albumin administration. Beta-blocker therapy was progressively discontinued after complete endoscopic eradication of varices. The clinical and biological evaluation was then repeated. The presence of PICD was defined as an increase in PRC of at least 50% above baseline 1 week after paracentesis.
RESULTS: Ten patients were included (nine men, mean age 59.1 ± 10.7 years old). The MELD score was 17.7 ± 4.4 and eight patients were Child-Pugh C. When patients were given beta-blockers, the heart rate did not change immediately after paracentesis while mean arterial pressure significantly decreased; PICD developed in eight patients. After beta-blockers were discontinued, the heart rate significantly increased immediately after paracentesis and mean arterial pressure significantly decreased; PICD only developed in one patient; the difference in the incidence of PICD was significant when these same patients were treated with beta-blockers.
CONCLUSIONS: The use of beta-blockers may be associated with a high risk of PICD in patients with cirrhosis and refractory ascites.
Authors:
Thomas Sersté; Claire Francoz; François Durand; Pierre-Emmanuel Rautou; Christian Melot; Dominique Valla; Richard Moreau; Didier Lebrec
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2011-02-24
Journal Detail:
Title:  Journal of hepatology     Volume:  55     ISSN:  0168-8278     ISO Abbreviation:  J. Hepatol.     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-09-19     Completed Date:  2011-11-21     Revised Date:  2012-01-25    
Medline Journal Info:
Nlm Unique ID:  8503886     Medline TA:  J Hepatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  794-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Affiliation:
INSERM, U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3 Clichy, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / administration & dosage,  adverse effects*
Aged
Ascites / physiopathology,  therapy*
Blood Pressure / drug effects,  physiology
Cardiovascular Diseases / chemically induced*,  physiopathology
Combined Modality Therapy
Creatinine / blood
Cross-Over Studies
Female
Follow-Up Studies
Heart Rate / drug effects,  physiology
Humans
Liver Cirrhosis / drug therapy*,  physiopathology
Male
Middle Aged
Paracentesis / adverse effects*
Propranolol / administration & dosage,  adverse effects*
Renin / blood
Sodium / blood
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 525-66-6/Propranolol; 60-27-5/Creatinine; 7440-23-5/Sodium; EC 3.4.23.15/Renin
Comments/Corrections
Comment In:
J Hepatol. 2011 Oct;55(4):743-4   [PMID:  21396970 ]
J Hepatol. 2012 Jan;56(1):298-9   [PMID:  22173037 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Naringenin Inhibits the Assembly and Long-Term Production of Infectious Hepatitis C Virus Particles ...
Next Document:  Hemochromatosis gene and nonalcoholic fatty liver disease: a systematic review and meta-analysis.